EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment of pancreatic cancer in 2022

Raffaella Casolino iD, Andrew V Biankin

Cambridge Prisms: Precision Medicine · 2023

DOI: 10.1017/pcm.2023.2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cambridge Prisms: Precision Medicine, 2023. Verfasst von Raffaella Casolino und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at an advanced, incurable, stage and has an extremely poor prognosis. Systemic chemotherapy represents the standard treatment either in the pre-operative, adjuvant and palliative setting, which is associated with only modest improvement in survival. More recently, advances in cancer genomic sequencing have unravelled the molecular heterogeneity of PDAC and identified small patient subgroups harbouring unique actionable aberrations in BRCA , NTRK , NRG1 and mismatch repair genes paving the way to a more personalised approach for this tumour. However, the evolution of PDAC treatment towards a successful precision approach presents many challenges. In this review, we discuss the current standard treatments of PDAC, from early stage to advanced disease, and we illustrate the opportunities and challenges of precision medicine for this deadly cancer.

Schlagwörter

Stichwörter der Autor:innen

cancerclinical trialspancreatic cancerprecision medicinetherapeuticstreatment approaches

Autor:innen und Institutionen

  • Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW, Australia.

ORCID-Profile: Raffaella Casolino

Zitieren

APA

Casolino, R., & Biankin, A. V. (2023). Treatment of pancreatic cancer in 2022. Cambridge Prisms: Precision Medicine. https://doi.org/10.1017/pcm.2023.2

Vancouver

Casolino R, Biankin AV. Treatment of pancreatic cancer in 2022. Cambridge Prisms: Precision Medicine. 2023. doi:10.1017/pcm.2023.2

BibTeX
@article{Casolino2023,
  author = {Casolino, Raffaella and Biankin, Andrew V},
  title = {Treatment of pancreatic cancer in 2022},
  journal = {Cambridge Prisms: Precision Medicine},
  year = {2023},
  doi = {10.1017/pcm.2023.2}
}
Kostenlos starten →